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Abstract: Different components of the autonomic nervous system may be affected by different disorders to varying de-
grees. The aim of this study is to report first experiences with a new device (FAN®, Schwarzer, Germany) which meas-
ures heart rate variability (HRV), sympathetic skin responses (SSR) and the pulse wave transit time (PTT). We examined 
190 healthy volunteers (102 men, 88 women) and in 89 subjects (46 men, 43 women) PTT during VM was investigated. 
In a subset of 24 subjects PTT was compared to conventional blood pressure recording. Thereafter, normal data were 
compared to patients with polyneuropathy (PNP) and Parkinson syndromes. All parameters of HRV decreased with age. 6 
parameters for HRV at rest, during deep respiration and the valsalva ratio were reclassified into three age categories: un-
der 40 (n=96), 40 – 60 (n=71) and 60 or older (n=23). Applying the lower limits of normal (5%-tile) subjects did not have 
more than 2 of these 6 parameters in the pathological range PTT reduction during phase IV of the valsalva manoeuvre was 
greater than 7.7 ms (5%-tile) but not age dependent. Patients with PNP had reduced HRV and SSR, Parkinson patients 
had more frequently impaired blood pressure regulation according to PTT assessment. Our investigation shows that the 
FAN® might be useful for clinicians to detect autonomic disorders.  
INTRODUCTION 
  The autonomic nervous system has three major compo-
nents: Parasympathetic (mainly vagal), sympathetic 
noradrenergic (vasoconstrictive) and sympathetic cholinergic 
(sudomotor). All three components may be affected by dif-
ferent disorders to varying degrees. In orthostatic hypoten-
sion, which occurs in Parkinson syndromes, sympathetic 
adrenergic failure may be predominant [1-3]. In diabetic 
neuropathies, reduction of the vagally mediated heart rate 
variability can be one of the first symptoms to appear [4-9] 
and in metabolic neuropathies, such as Fabry’s disease, su-
domotor failure occurs early while noradrenergic function is 
preserved [10-12].The measurement of heart rate variability 
(HRV) is clinical routine in most autonomic labs. In contrast 
to these cardio-vagal investigations, it is much more compli-
cated to get quantitative information about sympathetic 
nervous system function. The quantitative assessment of 
sudomotor function often requires a very sophisticated 
equipment [13]. This is why the sympathetic skin response 
(SSR), which is a more qualitative approach for the assess-
ment of the sweat gland function, was chosen, as SSR can be 
obtained using standard electromyographic machines [14]. 
For quantification of blood pressure responses (e.g during 
standing up or tilting) beat-to beat blood pressure monitoring 
is required [15, 16]. Unfortunately such monitors are very 
expensive limiting their clinical use. The reason we per-
formed this study was to report the clinical application of a 
new device which permits the recording of HRV, blood pres-
sure response and the assessment of the SSR with the same  
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hardware. The FAN® (Schwarzer, Germany) records HRV 
and SSR based on the standard recording techniques and 
algorithms used already in autonomic function studies [17, 
18]. Blood pressure changes, however, are estimated using 
the pulse transit time (PTT). PTT has been proposed to be a 
substitute for the direct measurement of blood pressure [19], 
in particular if not the absolute values but blood pressure 
changes are to be detected [20, 21]. Since PTT requires only 
simultaneous recording of standard ECG and a pulse wave 
using photoplethysmography, it simplifies the measurement 
of blood pressure responses. Although a first study using the 
FAN® to assess autonomic function has been published [22] 
there are no reports about normal values assessed by the 
FAN®. Since it is generally accepted that autonomic func-
tion parameters are significantly related to age [23] we inves-
tigated a sufficient number of healthy subjects. Using PTT is 
new in the routine assessment of autonomic function pa-
rameters therefore we compared PTT to standard beat-to-
beat blood pressure recordings in a subset of these subjects. 
In order to estimate the clinical significance we thereafter 
compared our normative data to patients with suspected 
autonomic disorders. 
MATERIALS AND METHODOLOGY 
Subjects 
  Normal subjects were 190 volunteers free of any illnesses 
affecting the heart and the nervous system. 102 of these sub-
jects were men, 88 women. The mean age was 42.9 years, 
ranging from 16 to 88. Care was taken that none of the sub-
jects were under any medication directly affecting heart rate 
(vagally or sympathetically). In this respect, ß-blockers, an-
tidepressants and antihypertonics were the most important to 
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consider. Furthermore, the volunteers were instructed to ab-
stain from smoking and drinking coffee on the day of inves-
tigation. In all subjects, HRV was assessed according to the 
protocol given below. In ten of the subjects (2 men, 8 
women, mean age 29.0 years (21-51), HRV tests were re-
peated on another day in order to estimate test-retest reliabil-
ity. In 89 normal subjects (46 men, 43 women, mean age 
42.8 years, range 21-88), the PTT change during Valsava 
manoeuvre was assessed. This measurement was performed 
twice in all 89 subjects. In 24 of these PTT was compared to 
standard beat-to-beat blood pressure measurement using a 
blood pressure monitor (Finapres; FMS, Amsterdam, The 
Netherlands). The sequence of PTT and blood pressure 
measurement was balanced. In order to assess the discrimi-
nating value of our normal data, two groups of patients, in 
whom autonomic dysfunction was common, were investi-
gated. The first group were 34 patients with sensory-motor 
polyneuropathy (PNP). PNP was diagnosed clinically and 
confirmed by nerve conduction studies. The aetiology of 
PNP was diverse. Main causes were diabetes, alcoholism, 
paraneoplasia and vitamin B 12 deficiency. The mean age of 
PNP patients was 55.9 years, ranging from 25 to 80. The 
second group of patients consisted of 22 patients with Park-
inson syndromes. According with clinical criteria, patients 
were classified as typical and atypical (including suspicious 
multiple system atrophy). For the purpose of our study, all 
Parkinson syndrome patients were pooled. The mean age in 
this patient group (11 men and 11 women) was 67 (range 46-
83). For obvious reasons, all patients were treated with anti-
Parkinson medication (L-Dopa, dopaminagonists, aman-
tadine) which may have interfered with autonomic function 
tests. In the same way as with the normal subjects, patients 
were instructed not to take ß-blockers, antidepressants or 
antihypertonics before measurement.  
Investigation Protocol 
  As a prerequisite, patients and normal subjects were in-
vestigated during morning hours and laid supine for at least 
20 minutes in our temperature controlled lab before starting 
the investigations. At first, heart rate variation during deep 
respiration was assessed; thereafter, the valsalva manoeuvre 
was performed and, finally, the heart rate variability at rest 
for 2 minutes and the heart rate response to active standing 
up were assessed.  
  After finishing the HRV assessment, the blood pressure 
response to the valsalva manoeuvre was assessed. PTT 
measurement was performed two times; beat-to-beat blood 
pressure was assessed on the same occasion. 
  The sympathetic skin response was assessed in patients at 
the end of the session. Description of the FAN®: 
  The FAN® has several major components. The most 
important one is an interface box for recording of ECG, SSR, 
breathing frequency and expiratory pressure e.g. during val-
salva manoeuvre. ECG, SSR and breathing frequency were 
digitized with a sampling rate of 500 Hz; the expiratory pres-
sure can be recorded with the limits of 0-100 mm mercury. 
The interface also offers the opportunity to record one ana-
logue external signal such as the pulse-wave or the blood 
pressure from an external monitor (digitizing rate 500 Hz). 
The interface also supplies acoustical (1 kHz, 0-100 dB, du-
ration 10-1000ms) and electrical outputs (square wave pulse, 
0-30mA, 0.2 ms duration) for triggering the SSR. The sec-
ond component is a so-called “feedback box”, which dis-
plays a bar moving up and down indicating the selected 
rhythm of breathing for the subjects. Close to the moving bar 
the actual breathing is displayed by LEDs moving up and 
down according to the breast excursions. This allows a feed-
back control of breathing. The third component is a Laptop 
PC to process the signals. Internal software automatically 
extracts relevant parameters (as described below) but also 
allows the definition of new parameters and test designs. The 
last component is a printer to make a hard copy of the re-
sults. 
  Heart rate variability (HRV): Subjects were instructed to 
perform 6 rhythmic breathing cycles per minute by observ-
ing the bar moving up and down on the feed-back box. In 
order to control breathing, a sensor was attached to the sub-
jects’ chests. If necessary, subjects’ breathing was displayed 
on the feedback monitor close to the moving bar. Heart rate 
was recorded by standard ECG electrodes fixed at the ex-
tremities. During three minutes of deep respiration, the me-
dian value of the maximum differences between the longest 
and shortest R-R intervals (max-min) and the median ratio of 
the longest and shortest R-R intervals (max/min) within the 
18 (=3 x 6/min) breathing cycles were calculated. In addi-
tion, the coefficient of variation (VC) and the root mean 
square of successive differences (RMSSD) of all R-R inter-
vals were obtained. 
  The Valsalva manoeuvre (VM) was performed after one 
minute of sitting. After this time, the subjects were instructed 
by an acoustic beep to maintain an expiratory pressure of 40 
mm mercury for 15 seconds. The 40 mm mercury value was 
displayed as a bar on the feedback control box and the pa-
tient´s expiratory pressure was displayed close beneath. The 
Valsalva ratio (VR) was calculated on the basis of the long-
est R-R interval within 30 seconds after the manoeuvre and 
the shortest R-R interval during or within the first five sec-
onds after the manoeuvre. 
  HRV at rest was recorded when the subjects lay supine 
for 5 minutes. Breathing cycles were not feedback controlled 
during this test. The important variables were VC and 
RMSSD within these 5 minutes. 
  Directly following HRV at rest, subjects were instructed 
by an acoustic beep to stand up and stay upright for one 
minute. The posture index (PI) was calculated on the basis of 
the longest R-R interval (20 – 40 heartbeats) and the shortest 
R-R interval (5- 25 heartbeats) after standing up [17]. 
Blood Pressure Regulation During VM 
  As a surrogate of beat to beat blood pressure, the pulse 
wave latency (PTT) was employed. The PTT was calculated 
by measuring the interval between the R wave of the ECG 
and the onset of the pulse wave, which was recorded on the 
right earlobe by a photoplethysmograph. The VM causes a 4-
tailed blood pressure response. It has been shown that late 
phase II and phase IV depend on the function of the auto-
nomic and, in particular, sympathetic nervous system. Since 
late phase II is poorly defined on a time basis, this study fo-
cuses on phase IV, the blood pressure overshoot (= PTT re-
duction in relation to baseline) after the VM. Thus, two pa-
rameters were calculated, the mean PTT at rest during 30 
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PTTs within 15 seconds after the end of the VM. PTT as-
sessment during VM was performed two times consecu-
tively. In a subset of subjects (n=24) the VM was repeated a 
third time. Now instead of PTT, beat-to-beat blood pressure 
was directly recorded by a Finapres® monitor and the signal 
was imported into the FAN®. Due to the fact that the FAN® 
allows to connect only one external signal, PTT and blood 
pressure must be recorded subsequently.  
Sympathetic Skin Response (SSR) 
  The SSR was described more than 100 years ago. Briefly, 
SSR mainly depends on the differential activation of sweat 
glands under emotional control at glabrous skin on palms 
and soles, and thermoregulatory controlled sweat glands on 
hairy skin. This differential activation can be recorded as a 
skin potential. Any arousal activates predominantly “emo-
tional” sweat glands, which causes a change of the skin po-
tential. SSR amplitude in healthy subjects varies substan-
tially on different occasions and the latency of this very slow 
potential is hard to define. However, it has been shown that 
SSR can be elicited in any healthy subject [14]. Therefore 
we abstained from collecting useless normative data and 
focused solely on the presence of the SSR on patients´ feet. 
The SSR was elicited by the FAN employing a 100 dB 
acoustic beep.  
Statistical Analysis 
  Statistical analysis was performed using the software 
package “SPSS 10.0 for windows” (SPSS Inc., Chicago, Ill., 
USA). In order to analyze the dependence of the different 
parameters (HRV and PWL) on age, height and weight, a 
logarithmic regression was chosen. Influences of sex or 
smoking habits were determined employing an univariate 
ANOVA for each variable. The lower limit of normal values 
was determined as the 5% percentile. Test-retest reliability 
was estimated using the Pearson correlation coefficient. 
Healthy control subjects and patients were compared with an 
ANCOVA model adjusted for age. Parameters were pre-
sented as mean +/- SD, where applicable. Significance was 
considered if p < 0,05 was reached. 
RESULTS  
  Normal values and test-retest reliability of standard 
parameters of heart rate variation (HRV). 
  All 8 parameters of heart rate variation decreased with 
age in perfect alignment with a logarithmic curve. This is 
applicable to the four parameters during two minutes of deep 
respiration (max-min, max/min, VC, RMSSD), the Valsalva 
Ratio (VR), the two parameters during 5 minutes at rest (VC, 
RMSSD) and the posture index.  
  For obvious reasons, max/min during deep respiration,   
VR and posture index cannot be less than one. Plotting indi- 
vidual values against age revealed that the calculated 5%-tile  
line did not cross this border in the VR. The lower limit of  
max/min during deep respiration, however, crossed 1 on the  
Y-axis below the age of 50, and the lower limit of the pos- 
ture index was never greater than 1 (see Fig. 1 and 2). There- 
fore, these two values were dropped from further analysis. 
  Subsequently, normal subjects were reclassified into 
three age groups: below 40 (n=96), 40– 60 (n=71) and 60 or 
older (n=23). The respective lower limits of normal values of 
all parameters are shown in Table 1. Using these limits, the 
individual values of all subjects were reclassified as “nor-
mal” or “pathological”. 95% of normal subjects had 2, or 
less, of all 8 possible parameters in the pathological range. 
Recalculation without the min/max ratio during deep respira-
tion and the posture index even leads to the result: 96,3 % 














Fig. (1). All parameters of heart rate variability decrease logarithmically with age. This graph illustrates distribution of individual RMSSD 















































Fig. (2). This graph illustrates distribution of individual coefficient of variation values during deep respiration. Lines indicate mean, 95% CI 


















Fig. (3). Using the lower limits of normal of 6 HRV parameters normal subjects were reclassified as “normal” or “pathological”. 96% of the 
normal subjects had 2 or less of 6 parameters in the pathological range.  
  In general, neither body weight nor height played signifi-
cant roles, with one exception: the valsalva ratio increased 
with increasing height (F=4.86, p<0.03). Sex or smoking 
habits had no effect on HRV parameters (F< 2 in any case, 
ns, ANOVA). 
  Test – retest variability (n=10) was moderate and was 
maximised for HRV during deep respiration, which was con-
trolled by feedback breathing, and at rest. It was fairly low if 
more active participation of subjects was required (VR and 
posture index). For details, see Table 2. 
  PTT during Valsalva manoeuvre (n=89): The blood pres-
sure overshoot during phase IV of the VM, namely the re-
duction of PTT in relation to the baseline, was neither sig-
nificantly affected by age (F=0.64,ns), nor height (F=0.02, 
ns) nor weight (F=0.98, ns). There was also no significant 
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(F=0.95). The 5% -tile of PTT reduction in phase IV was 
7.7. This means that a PWL reduction of 7.7, or more, as 
compared to mean PWL assessed during 30 seconds before 
the VM should be considered as normal. Test- retest reliabil-
ity within one experimental session was good. The results of 
the mean PTT before the VM were significantly correlated in 
both tests (r=0.83, p<0.001). The results for PTT reduction 
in phase IV of the VM in both sessions showed less but sig-
nificant autocorrelation (r=0.52, p<0.001, Fig. 4). However, 
test - retest reliability was poor if the test was repeated sev-
eral weeks later (n=10) and did not reach significance for 
mean PWL before VM (r=-0.57) and PWL reduction during 
phase IV (r=0.17).  
  In the comparative analysis of PTT and beat-to-beat 
blood pressure (n=24) PTT at rest was 154 +/- 19.2 ms and 
during phase IV of the VM 144 +/- 17.3 ms (p<0.001). As 
expected blood pressure increased during phase IV (systolic 
blood pressure at rest 124 +/-20.5 mmHg, phase IV 150 +/- 
29 mmHg, p<0.001; diastolic blood pressure at rest 65 +/-10 
mmHg, phase IV 74 +/- 12.7 mmHg, p<0.001; mean blood 
pressure at rest 95 +/-13.3 mmHg, phase IV 112 +/- 19.7 
mmHg, p<0.001) while heart rate slightly but significantly 
increased (at rest 69 +/- 8.6 min-1; phase IV 72 +/-9.5 min-1, 
p<0.001).  
  Correlation analysis revealed that before VM systolic 
blood pressure at rest (r=-0.59, p<0.005) and mean blood 
pressure (r=-0.50, p<0.02) were both negatively correlated to 
PTT. After VM (phase IV) only the heart rate was positively 
correlated to PTT (r=0.52, p<0.01). All other parameters 
(including the differences between phase IV and baseline) 
Table 1.  Listed are the Lower Limits of Normal for Each Parameter of HRV Corresponding to the Three Different Age Groups. 
Max/min During Deep Respiration and the Posture Index, which do not Significantly Contribute to Normal Data, are 
Marked in Grey 
Age   n  DR: VC  DR: RMSSD  DR: max-min  VR   Rest: VC  Rest: RMSSD  DR: max/min  PI 
<40 96  4.63  21.03  87.20  1.36 3.57  16.27  1.11  1.06 
40-60 71  3.10  12.88  46.00  1.19  2.37  11.29  1.05  1.06 
>60 23  2.13  7.24  25.40  1.13 1.40  8.97  1.03  1.03 
DR = deep respiration; VM = valsalva manoeuvre; Rest = HRV at rest; PI = posture index , VC = coefficient of variation; RMSSD = root mean square of successive differences. 
 
Table 2.  Statistical Evaluation of Test- Retest Correlation (n=10). Max/min During Deep Respiration and the Posture Index, which 
do not Significantly Contribute to Normal Data, are Marked in Grey 
Statistical value   DR: VC  DR: RMSSD  DR: max-min  VR   Rest: VC  Rest: RMSSD  DR: max/min  PI 
Pearson  r  0.794  0.697 0.709 0.248 0.188 0.709 0.736  0.529 
p-value  <0.01  <0.03  <0.03 n.s.  n.s. <0.03  <0.02  n.s. 











Fig. (4). In 89 of normal subjects PTT change during Valsava manoeuvre (VM) was performed twice. Significant test- retest correlation 
(r=0.52, p<0.001) is shown. Evaluation of the Autonomic Nervous System Using the FAN Device  The Open Neurology Journal, 2008, Volume 2    17 
were not correlated to absolute PTT at rest, during phase IV 
or PTT difference between both time points. 
Comparison Between Normative Data and Patients 
Groups 
  In a group analysis, patients with polyneuropathy showed 
reduced heart rate variability. Using an ANCOVA model 
adjusted for age, parameters obtained for these PNP patients 
during deep respiration and the coefficient of variation at rest 
were significantly lower than those from the control subjects. 
The Valsalva ratio and RMSSD at rest failed to distinguish 
between PNP patients and control subjects. Highest F-scores 
were found with the coefficient of variation both during deep 
respiration and at rest (Table 3). 
  On an individual basis, 8 of 34 patients fulfilled the crite-
ria of “pathological HRV”. This means they had more than 2 
of 6 HRV parameters in the pathological range. Blood pres-
sure regulation, as assessed by PTT reduction in phase IV of 
the VM, was also reduced in the PNP patients group (F=5.0, 
p<0.03). Individual analysis, however, revealed that only 3 
of 34 patients were below the lower limit of normal values 
(PWL baseline – PWL phase IV < 7.7). 
  Heart rate variability was far less reduced in patients 
suffering from extrapyramidal disorders than in PNP 
patients. Just two parameters, the coefficient of variation 
during deep respiration (F=4.703, p<0.04) and the coefficient 
of variation at rest (F=4.128, p<0.05), were reduced. The 
remaining parameters were not different from control values. 
rameters were not different from control values. On an indi-
vidual basis only 1 of 22 patients had to be classified as hav-
ing “pathological HRV”.  
  Blood pressure regulation during phase IV of VM, how-
ever, was significantly impaired (F=10.074, p<0.005). Ac-
cordingly 5/22 patients had parameters below the lower lim-
its of the normal range. 
  Direct comparison of both patient groups revealed that 
blood pressure regulation was significantly more impaired in 
patients with Parkinson syndromes (F=5.446, p<0.03). 
Sympathetic Skin Response (SSR) 
  The SSR on the feet was not obtained from the control 
group but only from patients. In 6 / 34 neuropathy patients, 
SSR could not be obtained, five of them had “pathological 
HRV”. SSR could not be elicited in 5 / 22 Parkinson pa-
tients, but none of them had “pathological HRV”. 
DISCUSSION 
  Our results suggest that the FAN ® system (Schwarzer, 
Germany) might be well suited to comprehensively assess 
autonomic function. We were able to define and apply to 
different patients groups normal values for heart rate vari-
ability (HRV) and for pulse wave transit time (PTT) changes 
during Valsalva manoeuvre. In particular the latter result 
could simplify the assessment of blood pressure regulation in 













Fig. (5). PTT at rest was significantly correlated to systolic blood pressure (r=-0.59, p<0.005). 
Table 3.  Comparison Between Normal Subjects and Patients with Polyneuropathy. HRV was Significantly Reduced in the Patient 
Group. Max/min During Deep Respiration and the Posture Index, which do not Significantly Contribute to Normal Data, 
are Marked in grey 
Statistical value   DR: VC  DR: RMSSD  DR: max-min  VR   Rest: VC  Rest: RMSSD  DR: max/min  PI 
Ancova F  10.854  8.492  9.016  0.380  6.512  0.493  6.467  2.70 
p-value <0.01 <0.04 <0.005  n.s.  <0.02  n.s.  <0.02  n.s. 
DR = deep respiration; VM = valsava manoeuvre; Rest = HRV at rest; PI = posture index , VC = coefficient of variation; RMSSD = root mean square of successive differences. 18    The Open Neurology Journal, 2008, Volume 2  Haegele-Link et al. 
Reasonable Parameters to Assess HRV- the Normal Data 
  In a first step we defined lower limits of normal HRV 
investigating 190 normal subjects. All single parameters fol-
lowed a logarithmic decrease with age. This is in accordance 
with previous studies [23]. Other biological markers had no 
significant effect on HRV. Each parameter of HRV was plot-
ted against age and the lower limit of normal was defined as 
the 5%-tile of these data. This limit is moderately rigorous 
when compared to other studies [24]. The posture index and 
the max/min ratio during deep respiration had too huge a 
variability to define reasonable lower limits of normal. The 
posture index is further prone to movement artefacts and 
difficult to assess in, for example, bedridden patients [17]. 
Both parameters are therefore dispensable. For clinical rou-
tine, HRV parameters can be classified into three age groups 
(below 40, 40 to 60, 60 or older) [25]. Using this classifica-
tion 96% of our normal subjects had 2 or less of the remain-
ing 6 parameters of HRV in the pathological range. The as-
sessment of these 6 parameters is necessary because one 
parameter alone would obviously not be precise enough to 
diagnose cardiac autonomic failure, otherwise, these 25% of 
healthy subjects would have been misclassified. HRV is an 
indirect measure and may be influenced by blood volume, 
baroreceptor activity or vasoconstriction [26, 27]. This might 
be the reason why test-retest correlation was moderate. In 
particular when active participation is required, control of 
confounding variables seemed difficult [28-30].  
  The decrease of HRV in the time domain with age and 
the lack of sex effects were in good accordance with previ-
ous reports about normative date on HRV in normal subjects. 
[37, 38]. In these studies spectral analysis has been also used 
to study autonomic nervous system function, in particular for 
differentiation between parasyspathetic and sympathetic 
function. Since specificity of spectral HRV components has 
been questioned several times [39] we intentionally focused 
on the better defined time domain analysis in the present 
study. The FAN®, nevertheless provides quantitative data of 
Fast Fourier Transformation in the low (0.01-0.05 Hz), me-
dium (0.05-0.15 Hz) and high (0.15-0.50 Hz) frequency 
band. 
PTT as a Surrogate for Blood Pressure 
  For quantitative evaluation of blood pressure, continuous 
measurement is a prerequisite. However, continuous blood 
pressure measurement normally requires expensive, sophisti-
cated hardware [31]. PTT, the time lag between ECG and the 
physical pulse wave, has been shown in previous studies to 
be negatively correlated to systolic blood pressure during 
resting conditions, correlations to diastolic blood pressure 
and blood pressure changes during cold pressor test were 
weak [32, 33]. This is exactly what we found. While in rest-
ing periods there was a linear relationship between PTT and 
blood pressure, the correlation became obviously much more 
complicated if blood pressure dynamically changed. One 
possibility to increase the coherence between blood pressure 
and PTT would be to subtract pre-ejection period (the R-
wave/mechanical cardiac delay) for calculation of PTT [34]. 
Pre-ejection period has been shown to account for about 12-
35% of the variability of PTT to the fingers [33]. This could 
in particular increase the correlation between diastolic and 
mean blood pressure and PTT. Calculating the pre-ejection 
period, however, requires either cardiac bioimpedance meas-
urement [33] or phonocardiography [20]. This would level 
the major advantage of PTT – the ease of assessing. Al-
though there are no systematic investigations so far it seems 
obvious that another possibility to reduce the influence of the 
pre-ejection period would be to vary the site of pulse wave 
recording. We measured the pulse wave at the earlobe lead-
ing to a relatively short PTT (154 ms) and possibly a rela-
tively big pre-ejection period effect. Recording at the toe 
increases PTT to about 400 ms. Under these circumstances 
the pre-ejection effect might be minimized and correlation 
between PTT and arterial pressure could be enhanced [21]. 
  However, we never intended to introduce PTT as a sub-
stitute of absolute blood pressure recording. The PTT in our 
study must be regarded as a relative parameter. It allows only 
the estimation of blood pressure changes. Our results show 
that if this prerequisite is considered, PTT might indicate 
cardiovascular changes during VM as it has been shown be-
fore in hemodialysis [20] and spinal anesthesia [21]. PTT 
during VM shows an inverse picture of the well-known 
blood pressure response [35]. That is, there was PWL reduc-
tion during phase IV of the VM. We focussed on phase IV, 
since the evaluation routine of the FAN defines VM phases 
on a time-basis. Phase IIb is less reliably defined due to indi-
vidual differences [36]. We have been able to define lower 
limits of normal for phase IV and even test-retest reliability 
was fairly good within one session.  
The Significance of the Normal Values 
  In order to get an impression whether our normal data 
might be sensitive enough to detect autonomic disturbances 
we investigated patients with polyneuropathy and Parkinson 
syndromes. Polyneuropathy is associated with “cholinergic” 
autonomic failure - reduced HRV and absent SSR [14]. In 
our study eight patients had to be classified as “pathological 
HRV” and 6 of them also had absent SSR . This is a reason-
able number in an unselected population of neuropathy pa-
tients. Parkinson patients predominantly suffer from or-
thostatic hypotension (“adrenenergic”) rather than from im-
pairment of “cholinergic” function [2]. Accordingly Parkin-
son patients had predominant restriction of blood pressure 
regulation in our study.  
  We appreciate that our patients’ groups are inhomogene-
ous (neuropathy) and under medication (Parkinson’s dis-
ease). However, the aim of investigating patients in addition 
to normal subjects has been to provid an estimate about the 
value of our normal data to prove “normality”. This has been 
accomplished. For such a goal the cause of autonomic failure 
seems of minor importance.It was astonishing that we were 
able to detect exactly the pattern of autonomic failure which 
could be expected from previous studies. 
  In conclusion our study provides data showing that the 
FAN® might be a useful tool to assess different function 
parameters of the autonomic nervous system. In particular 
the assessment of PTT offers the opportunity to investigate 
large numbers of patients with sympathetic failure.  
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